Benedetta Conte
@BenedettaConte5
Followers
705
Following
832
Media
58
Statuses
421
Oncologist | Marie-Curie PhD fellow. Based in Barcelona @idibaps. Main focus: #CancerResarch #BreastCancer #TranslationalResearch
Barcellona, Spagna
Joined October 2018
Happy and honoured to be a Marie Skłodowska-Curie fellow! This European program has given me the opportunity to begin my PhD project on cancer metastasis at @idibaps with Prof @prat_aleix. I recommend all young researchers to check It out! ⬇️⬇️⬇️.
This year marks the 25th anniversary of the Marie Skłodowska-Curie Actions! 🎂. Inspired by the remarkable European scientist, the @MSCActions have become the reference programme for supporting researchers’ training not only in Europe but also worldwide.
2
0
28
Che bella sensazione leggere il nome di @filippoconte94 come autore di un pezzo su @LaStampa !!! .
lastampa.it
Il leader di Azione punta sull’uomo voluto da Meloni a commissario europeo. E sul campolargo: «Noi non faremo nessuna alleanza che non abbia solidissime basi p…
0
0
7
RT @evomet_itn: Hi from Vienna!.If you are in the city, join us tomorrow at @IMPvienna for the "Metastasis mechanisms workshop" with @johan….
0
3
0
RT @TomasPascualMD: I never imagined how fulfilling this would be. Thrilled to announce that our #DEFINITIVEtrial now has an NCT number: NC….
0
15
0
0
2
0
RT @matteolambe: Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative ad….
0
58
0
RT @Lucarecco: At #ASCO24 @matteolambe presents analysis on BRCA BCY Collaboration including young BRCA carriers affected by eBC:. ➡️ Diff….
0
17
0
RT @stolaney1: Patient-level meta-analysis shows HER2DX is associated with survival outcomes in patients with early-stage HER2+ BC presente….
0
25
0
RT @RevealGenomics: #ESMOBreast24 key takeaways.@lab_kok Wishlist includes #HER2DX and the development of to achiev….
0
3
0
Super importante conference! Do not miss it!! ⬇️⬇️⬇️⬇️⬇️.
0
3
5
RT @PTarantinoMD: Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussi….
0
33
0
RT @matteolambe: Proffered paper session 1 at #ESMOBreast24: first results from #DOLAF trial showing very promising activity in advanced ER….
0
7
0
RT @PabloMando: @CarmenCriscit approaching several controversies in the real world oncology in BRCA/HR+ adjuvant scenario.▪️How to choose b….
0
14
0
RT @OncoAlert: Just out 🚨on @eBioMedicine.Study explores the potential of a B-cell/immunoglobulin signature (IGG), alone or combined with t….
0
5
0
RT @MartaPerachino: 🎯 B-cell/immunoglobulin signature (IGG) was associated with improved EFS (HR = 0.77) and OS (HR = 0.79) across 7 cohort….
0
5
0
Very happy to see that our paper on @eBioMedicine is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix @evomet_itn @fara_bm.
Editor pick from April issue. @BenedettaConte5 @prat_aleix @fara_bm & coll. Identified a 14-gene immunoglobulin B-cell signature linked to improved prognosis and pathological complete response in patients with early-stage triple-negative breast cancer.Read
1
7
25
0
3
0
Soon, we will present more data on the biological and clinical meaning of this signature in aggressive BC subtypes, by using more refined approaches such as single-cell RNAseq. Stay tuned!.
0
0
3